Results 41 to 50 of about 9,484 (203)

A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

BMC Ophthalmology, 2012
Background Several studies have investigated the effect of latanoprost on intraocular pressure (IOP). We compared the IOP-lowering effects of three higher concentrations of latanoprost with the commercially available concentration of 0.005% (50 μg/mL) in
Eveleth David, Starita Carla, Tressler Charles   +2 more
doaj   +1 more source

Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery. [PDF]

, 2012
PurposeTo explore changes in central macular thickness (CMT) after a two-month period of glaucoma therapy with topical latanoprost after uneventful phacoemulsification.MethodsForty-one eyes of 31 patients with primary open angle or pseudoexfoliative ...
Amini, Heydar, Eslami, Yadollah, Fakhraie, Ghasem, Latifi, Golshan, Moghimi, Sasan, Nouri-Mahdavi, Kouros, Zandian, Mehdi, Zarei, Reza   +7 more
core   +1 more source

Profilatic use of apraclonidine and latanoprost to prevent intraocular pressure elevation following Nd:YAG laser posterior capsulotomy [PDF]

, 1999
Purpose: To compare the efficacy of 0.005% latanoprost and 1% apraclonidine in the prevention of an increase of intraocular pressure (IOP) after Nd: YAG laser capsulotomy in nonglaucomatous patients. Methods: Thirty-six patients were included and divided
Nassaralla Júnior, João Jorge, Paranhos Junior, Augusto, Paranhos, Juliane de Freitas S.   +2 more
core   +2 more sources

Comparison of Corneal Endothelial Imaging Techniques by Specular Microscopy in Unsedated Healthy Dogs

Veterinary Ophthalmology, Volume 29, Issue 3, May 2026.
ABSTRACT Objective To compare unsedated noncontact specular microscopy imaging techniques for the canine corneal endothelium and identify the most effective technique. Animals Studied Nineteen eyes of 10 systemically healthy, staff‐owned dogs with clinically normal corneas were studied.
Hyunwoo Suk, Minju Kim, Dohyeong Kim, Seonmi Kang, Kangmoon Seo   +4 more
wiley   +1 more source

Localized and controlled delivery of nitric oxide to the conventional outflow pathway via enzyme biocatalysis: towards therapy for Glaucoma [PDF]

, 2016
Nitric oxide (NO) has been shown to lower intraocular pressure (IOP), however its therapeutic effects on outflow physiology are location- and dose-dependent.
Chandrawati, R, Chang, J, Jumeaux, C, Overby, DR, Reina-Torres, E, Sherwood, JM, Stamer, WD, Stevens, MM, Zelikin, AN   +8 more
core   +1 more source

Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond

Advanced Science, Volume 13, Issue 23, 23 April 2026.
Therapeutic gases, including NO, CO, H2S, H2, CO2, O2, and Xe, play vital roles in cellular signaling and repair. This review highlights the emerging carriers and delivery systems that enable controlled, localized gas release for diagnostic and therapeutic applications.
Syed Muntazir Andrabi, Navatha Shree Sharma, Imran Ibn Gani Rather, S. M. Shatil Shahriar, Jingwei Xie   +4 more
wiley   +1 more source

Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost

Clinical Ophthalmology, 2020
Arindam Halder, Ajay J Khopade Formulation Department, Sun Pharmaceutical Industries, Ltd, Tandalja, Vadodara, IndiaCorrespondence: Ajay J KhopadeSun Pharmaceutical Industries, Ltd., Tandalja, Vadodara 390020, Gujarat, IndiaTel +91 22 6645 5645 Ext ...
Halder A, Khopade AJ
doaj  

A Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Latanoprost 0.005% and Timolol 0.5% Dosed Concomitantly in Patients with Open-Angle Glaucoma or Ocular Hypertension [PDF]

, 2011
Background/Aims: To compare the intraocular pressure (IOP)-lowering efficacy of travoprost 0.004%/timolol 0.5% in fixed combination with the unfixed combination of latanoprost 0.005% and timolol 0.5% in open-angle glaucoma or ocular hypertension patients
Bergamini, Michael VW, Landry, Theresa A, Mallick, Sushanta, Peace, James H, Rhee, Douglas J, Study Group   +5 more
core  

Pharmacogenetics of ophthalmic topical β-blockers [PDF]

, 2008
Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure.
McCarty, Catherine A., Patchett, Richard, Sidjanin, Duska J., Smith, Edward M., Wilke, Russell A.   +4 more
core   +1 more source

Drug‐Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database

Arthritis &Rheumatology, Volume 78, Issue 4, Page 985-992, April 2026.
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty, Loubna Dari, Jean‐Luc Cracowski, Matthieu Roustit, Charles Khouri   +4 more
wiley   +1 more source